Welcome to Medications.com

Bioalliance Pharma could be attractive target but no proposal on ... - Forbes

In the first half of 2009, Bioalliance aims to file for European approval of oral herpes treatment acyclovir Lauriad, followed in the second half, it hopes, ...

http://www.forbes.com/markets/fee... | Posted: Fri Feb 29 07:46:47 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea